Resistance to Raf inhibition in cancer

Drug Discovery Today: Technologies

Volumn 11, Issue 1, 2014, Pages 27-32

  Haarberg, H Eirik ^a   Smalley, Keiran S M ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE INHIBITOR; ANTINEOPLASTIC AGENT; B RAF KINASE; BRAF PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CLINICAL TRIAL (TOPIC); DISEASE RESISTANCE; GENE FREQUENCY; GENE MUTATION; HUMAN; MELANOMA; ONCOGENE; ANTAGONISTS AND INHIBITORS; DRUG RESISTANCE; METABOLISM; SIGNAL TRANSDUCTION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG RESISTANCE, NEOPLASM; HUMANS; MAP KINASE SIGNALING SYSTEM; MELANOMA; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS B-RAF; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 84899938158     PISSN: None     EISSN: 17406749     Source Type: Journal    
DOI: 10.1016/j.ddtec.2013.12.004     Document Type: Review

References (39)

1. I.V. Fedorenko et al. Acquired and intrinsic BRAF inhibitor resistance in BRAF V600E mutant melanoma Biochem Pharmacol 82 2011 201 209
2. C. Wellbrock et al. The RAF proteins take centre stage Nat Rev Mol Cell Biol 5 2004 875 885
3. H. Davies et al. Mutations of the BRAF gene in human cancer Nature 417 2002 949 954
4. P.T. Wan et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF Cell 116 2004 855 867
5. E. Tiacci et al. BRAF mutations in hairy-cell leukemia N Engl J Med 364 2011 2305 2315
6. G. Singer et al. Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma J Natl Cancer Inst 95 2003 484 486
7. M. Andrulis et al. Targeting the BRAF V600E mutation in multiple myeloma Cancer Discov 3 2013 862 869
8. H. Namba et al. Clinical implication of hot spot BRAF mutation, V599E, in papillary thyroid cancers J Clin Endocrinol Metab 88 2003 4393 4397
9. G. Bollag et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma Nature 467 2010 596 599
10. J.G. Greger et al. Combinations of BRAF, MEK, and PI3K/mtor inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations Mol Cancer Therap 11 2012 909 920
11. A. Hauschild et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial Lancet 380 2012 358 365
12. P.B. Chapman et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation N Engl J Med 364 2011 2507 2516
13. G.T. Gibney et al. Paradoxical oncogenesis - the long-term effects of BRAF inhibition in melanoma Nat Rev Clin Oncol 10 2013 390 399
14. O. Maertens et al. Elucidating distinct roles for NF1 in melanomagenesis Cancer Discov 3 2012 338 349
15. K.S. Smalley et al. Increased cyclin D1 expression can mediate BRAF inhibitor resistance in BRAF V600E-mutated melanomas Mol Cancer Ther 7 2008 2876 2883
16. K. Kim et al. Significant long-term survival benefit demonstrated with vemurafenib in ongoing phase I study Pigment Cell Melanoma Res 25 2012 866
17. S. Whittaker et al. Gatekeeper mutations mediate resistance to BRAF-targeted therapies Sci Transl Med 2 2010 35ra41
18. C.M. Johannessen et al. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation Nature 2010
19. R. Nazarian et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation Nature 468 2010 973 977
20. J. Villanueva et al. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K Cancer Cell 18 2010 683 695
21. T.R. Wilson et al. Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors Nature 487 2012 505 509
22. R. Straussman et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion Nature 487 2012 500-U118
23. A.M. Jubb et al. Impact of MET expression on outcome in BRAF advanced melanoma Histopathology 63 2013 351 361
24. P. Lito et al. Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas Cancer Cell 22 2012 668 682
25. A. Prahallad et al. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR Nature 483 2012 100 103
26. C.M. Johannessen et al. A melanocyte lineage program confers resistance to MAP kinase pathway inhibition Nature 504 2013 138 142
27. H.B. Shi et al. Preexisting MEK1 exon 3 mutations in (V600E/K)BRAF melanomas do not confer resistance to BRAF inhibitors Cancer Discov 2 2012 414 424
28. J. Villanueva et al. Concurrent MEK2 mutation and BRAF amplification confer resistance to BRAF and MEK inhibitors in melanoma Cell Reports 4 2013 1090 1099
29. P.I. Poulikakos et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E) Nature 480 2011 387-U144
30. K. Trunzer et al. Pharmacodynamic effects and mechanisms of resistance to vemurafenib in patients with metastatic melanoma J Clin Oncol 31 2013 1767 1774
31. K.L. Nathanson et al. Tumor Genetic Analyses of Patients with Metastatic Melanoma Treated with the BRAF Inhibitor Dabrafenib (GSK2118436) Clin Cancer Res 19 2013 4868 4878
32. K.T. Flaherty et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations N Engl J Med 367 2012 1694 1703
33. N. Wagle et al. Whole exome and whole transcriptome sequencing in melanoma patients to identify mechanisms to combined RAF/MEK inhibition J Clin Oncol 31 2013 9015
34. E.J. Morris et al. Discovery of a novel ERK inhibitor with activity in models of acquired resistance to BRAF and MEK inhibitors Cancer Discov 3 2013 742 750
35. K.H. Paraiso et al. The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms Clin Cancer Res 18 2012 2502 2514
36. X. Wu et al. Activity of the heat shock protein 90 inhibitor ganetespib in melanoma PLoS ONE 8 2013 e56134
37. H. Shi et al. A novel AKT1 mutant amplifies an adaptive melanoma response to BRAF inhibition Cancer Discov 2013 Nov 21. [Epub ahead of print]
38. K.S. Smalley et al. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases Mol Cancer Ther 5 2006 1136 1144
39. M. Mao et al. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents Clin Cancer Res 19 2013 657 667